Cystic fibrosis transmembrane regulator correctors and potentiators

Cold Spring Harbor Perspectives in Biology

Volumn 5, Issue 7, 2013, Pages

  Rowe, Steven M ^a   Verkman, Alan S ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879866267     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, et al. 2010. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 363: 1991-2003.
2. Bridges RJ. 2010. Capitalizing on corrector mechanistic differences to achieve synergy in F508del CFTR expression. Ped Pulmonol Suppl 45: 119-120.
3. Budriesi R, Ioan P, Leoni A, Pedemonte N, Locatelli A, Micucci M, Chiarini A, Galietta LJ. 2011. Cystic fibrosis: A new target for 4-Imidazo[2,1-b]thiazole-1,4-dihydropyridines. J Med Chem 54: 3885-3894.
4. Carlile GW, Robert R, Zhang D, Teske KA, Luo Y, Hanrahan JW, Thomas DY. 2007. Correctors of protein trafficking defects identified by a novel high-throughput screening assay. Chembiochem 8: 1012-1020.
5. Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, et al. 2011. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67: 12-18.
6. Dalemans W, Barbry P, Champigny G, Jallat S, Dott K, Dreyer D, Crystal RG, Pavirani A, Lecocq JP, Lazdunski M. 1991. Altered chloride ion channel kinetics associated with the DF508 cystic fibrosismutation. Nature 354: 526-528.
7. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ. 1992. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358: 761-764.
8. Du K, Sharma M, Lukacs GL. 2005a. The DF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR. Nat Struct Mol Biol 12: 17-25.
9. Du K, Sharma M, Lukacs GL. 2005b. The DF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR. Nat Struct Mol Biol 12: 17-25.
10. Eckford PD, Bear CE. 2011. Targeting the regulation of CFTR channels. Biochem J 435: e1-e4.
11. Egan ME, Pearson M, Weiner SA, Rajendran V, Rubin D, Glockner-Pagel J, Canny S, Du K, Lukacs GL, Caplan MJ. 2004. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 304: 600-602.
12. Eidelman O, Guay-Broder C, van Galen PJ, Jacobson KA, Fox C, Turner RJ, Cabantchik ZI, Pollard HB. 1992. A1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells. Proc Natl Acad Sci 89: 5562-5566.
13. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT. 2006. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 354: 229-240.
14. Flume PA, Borowitz DS, Liou TG, Li K, Yen K, Ordonez CL, Geller DE. 2011. VX-770 in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. J Cyst Fibros 10: S16.
15. Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordonez CL, Geller DE. 2012. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 142: 718-724.
16. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME. 1994. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 331: 637-642.
17. Galietta LJ, Haggie PM, Verkman AS. 2001a. Green fluorescent protein-based halide indicators with improved chloride and iodide affinities. FEBS Lett 499: 220-224.
18. Galietta LV, Jayaraman S, Verkman AS. 2001b. Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists. AmJ Physiol Cell Physiol 281: C1734-C1742.
19. Goss CH, Genatossio A, Rowbotham RK, Hamblett N, McNamara S, Knowles M, Brass-Ernst L, Aitken ML, Zeitlin PL, Boyle MP. 2006. A phase I safety and dose finding study of orally administered curcuminoids in adult subjects with cystic fibrosis who are homozygous for DF508 cystic fibrosis transmembrane conductance regulator. Ped Pulmonol Suppl 41: 247.
20. Grove DE, Rosser MF, Ren HY, Naren AP, Cyr DM. 2009. Mechanisms for rescue of correctable folding defects in CFTRDF508. Mol Biol Cell 20: 4059-4069.
21. Grubb BR, Gabriel SE, Mengos A, Gentzsch M, Randell SH, Van Heeckeren AM, Knowles MR, Drumm ML, Riordan JR, Boucher RC. 2006. SERCA pump inhibitors do not correct biosynthetic arrest of DF508 CFTR in cystic fibrosis. Am J Respir Cell Mol Biol 34: 355-363.
22. Guay-Broder C, Jacobson KA, Barnoy S, Cabantchik ZI, Guggino WB, Zeitlin PL, Turner RJ, Vergara L, Eidelman O, Pollard HB. 1995. A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator DF508 mutation. Biochemistry 34: 9079-9087.
23. He L, Aleksandrov LA, Cui L, Jensen TJ, Nesbitt KL, Riordan JR. 2010. Restoration of domain folding and interdomain assembly by second-site suppressors of the DF508 mutation in CFTR. FASEB J 24: 3103-3112.
24. Hutt DM, Herman D, Rodrigues AP, Noel S, Pilewski JM, Matteson J, Hoch B, KellnerW, Kelly JW, Schmidt A, et al. 2010. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol 6: 25-33.
25. Jayaraman S, Haggie P, Wachter RM, Remington SJ, Verkman AS. 2000. Mechanism and cellular applications of a green fluorescent protein-based halide sensor. J Biol Chem 275: 6047-6050.
26. Jurkuvenaite A, Chen L, Bartoszewski R, Goldstein R, Bebok Z, Matalon S, Collawn JF. 2010. Functional stability of rescued DF508 cystic fibrosis transmembrane conductance regulator in airway epithelial cells. Am J Respir Cell Mol Biol 42: 363-372.
27. Kalid O, Mense M, Fischman S, Shitrit A, Bihler H, Ben-Zeev E, Schutz N, Pedemonte N, Thomas PJ, Bridges RJ, et al. 2010. Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening. J Comput Aided Mol Des 24: 971-991.
28. Kim Chiaw P, Wellhauser L, Huan LJ, Ramjeesingh M, Bear CE. 2010. Achemical corrector modifies the channel function of F508del-CFTR. Mol Pharmacol 78: 411-418.
29. Lin S, Sui J, Cotard S, Fung B, Andersen J, Zhu P, El Messadi N, Lehar J, Lee M, Staunton J. 2010. Identification of synergistic combinations of F508del cystic fibrosis transmembrane conductance regulator (CFTR) modulators. Assay Drug Dev Technol 8: 669-684.
30. Loo TW, Bartlett MC, Clarke DM. 2008. Correctors promote folding of the CFTR in the endoplasmic reticulum. Biochem J 413: 29-36.
31. Lubamba B, Lecourt H, Lebacq J, Lebecque P, De Jonge H, Wallemacq P, Leal T. 2008. Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med 177: 506-515.
32. Lukacs GL, Chang XB, Bear C, Kartner N, Mohamed A, Riordan JR, Grinstein S. 1993. The DF508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. J Biol Chem 268: 21592-21598.
33. Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, Galietta LJ, Verkman AS. 2002a. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 110: 1651-1658.
34. Ma T, Vetrivel L, Yang H, Pedemonte N, Zegarra-Moran O, Galietta LJ, Verkman AS. 2002b. High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by highthroughput screening. J Biol Chem 277: 37235-37241.
35. McCarty NA, Standaert TA, Teresi M, Tuthill C, Launspach J, Kelley TJ, Milgram LJ, Hilliard KA, Regelmann WE, Weatherly MR, et al. 2002. A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis. Pediatr Pulmonol 33: 90-98.
36. Mills AD, Yoo C, Butler JD, Yang B, Verkman AS, Kurth MJ. 2010. Design and synthesis of a hybrid potentiator-corrector agonist of the cystic fibrosis mutant protein DF508-CFTR. Bioorg Med Chem Lett 20: 87-91.
37. Mu TW, Ong DS, Wang YJ, Balch WE, Yates JR 3rd, Segatori L, Kelly JW. 2008. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 134: 769-781.
38. Muanprasat C, Sonawane ND, Salinas D, Taddei A, Galietta LJ, Verkman AS. 2004. Discovery of glycine hydrazide pore-occluding CFTR inhibitors: Mechanism, structure-activity analysis, and in vivo efficacy. J Gen Physiol 124: 125-137.
39. Namkung W, Phuan PW, Verkman AS. 2011a. TMEM16A inhibitors reveal TMEM16A as a minor component of calcium-activated chloride channel conductance in airway and intestinal epithelial cells. J Biol Chem 286: 2365-2374.
40. Namkung W, Yao Z, Finkbeiner WE, Verkman AS. 2011b. Small-molecule activators of TMEM16A, a calcium-activated chloride channel, stimulate epithelial chloride secretion and intestinal contraction. FASEB J 25: 4048-4062.
41. Noel S, Wilke M, Bot AG, De Jonge HR, Becq F. 2008. Parallel improvement of sodium and chloride transport defects by miglustat (n-butyldeoxynojyrimicin) in cystic fibrosis epithelial cells. J Pharmacol Exp Ther 325: 1016-1023.
42. Norez C, Antigny F, Noel S, Vandebrouck C, Becq F. 2009. A cystic fibrosis respiratory epithelial cell chronically treated by miglustat acquires a non-cystic fibrosis-like phenotype. Am J Respir Cell Mol Biol 41: 217-225.
43. Ostedgaard LS, Rogers CS, Dong Q, Randak CO, Vermeer DW, Rokhlina T, Karp PH, Welsh MJ. 2007. Processing and function of CFTR-DF508 are species-dependent. Proc Natl Acad Sci 104: 15370-15375.
44. Pasyk S, Li C, Ramjeesingh M, Bear CE. 2009. Direct interaction of a small-molecule modulator with G551DCFTR, a cystic fibrosis-causing mutation associated with severe disease. Biochem J 418: 185-190.
45. Pedemonte N, Lukacs GL, Du K, Caci E, Zegarra-Moran O, Galietta LJ, Verkman AS. 2005a. Small-molecule correctors of defective DF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 115: 2564-2571.
46. Pedemonte N, Sonawane ND, Taddei A, Hu J, Zegarra-Moran O, Suen YF, Robins LI, Dicus CW, Willenbring D, Nantz MH, et al. 2005b. Phenylglycine and sulfonamide correctors of defective DF508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol 67: 1797-1807.
47. Pedemonte N, Tomati V, Sondo E, Caci E, Millo E, Armirotti A, Damonte G, Zegarra-Moran O, Galietta LJ. 2011. Dual activity of aminoarylthiazoles on the trafficking and gating defects of the cystic fibrosis transmembrane conductance regulator chloride channel caused by cystic fibrosis mutations. J Biol Chem 286: 15215-15226.
48. Phuan PW, Yang B, Knapp J, Wood A, Lukacs GL, Kurth MJ, Verkman AS. 2011. Cyanoquinolines with independent corrector and potentiator activities restore DF508-CFTR chloride channel function in cystic fibrosis. Mol Pharmacol 80: 683-693.
49. Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch WE. 2009. Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem 78: 959-991.
50. Pyle LC, Ehrhardt A, Mitchell LH, Fan L, Ren A, Naren AP, Li Y, Clancy JP, Bolger GB, Sorscher EJ, et al. 2011. Regulatory domain phosphorylation to distinguish the mechanistic basis underlying acute CFTR modulators. Am J Physiol Lung Cell Mol Physiol 301: L587-L597.
51. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, et al. 1999. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 340: 23-30.
52. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, et al. 2011. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New Engl J Med 365: 1663-1672.
53. Robert R, Carlile GW, Pavel C, Liu N, Anjos SM, Liao J, Luo Y, Zhang D, Thomas DY, Hanrahan JW. 2008. Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol Pharmacol 73: 478-489.
54. Robert R, Carlile GW, Liao J, Balghi H, Lesimple P, Liu N, Kus B, Rotin D, Wilke M, de Jonge HR, et al. 2010. Correction of the D Phe508 cystic fibrosis transmembrane conductance regulator trafficking defect by the bioavailable compound glafenine. Mol Pharmacol 77: 922-930.
55. Rogers CS, Stoltz DA, Meyerholz DK, Ostedgaard LS, Rokhlina T, Taft PJ, Rogan MP, Pezzulo AA, Karp PH, Itani OA, et al. 2008. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science 321: 1837-1841.
56. Rowe SM, Accurso F, Clancy JP. 2007. Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. Proc Am Thorac Soc 4: 387-398.
57. Rowe SM, Clancy JP, Boyle M, Van Goor F, Ordonez C, Dong Q, Campbell P, Ashlock M, Accurso F. 2010. Parallel effects of VX-770 on transepithelial potential difference in vitro and in vivo. J Cystic Fibrosis 9 (Suppl): S20.
58. Rubenstein RC, Zeitlin PL. 1998. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in DF508-homozygous cystic fibrosis patients: Partial restoration of nasal epithelial CFTR function. AmJ Respir Crit Care Med 157: 484-490.
59. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW III, et al. 2003. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial. JAMA 290: 1749-1756.
60. Sampson HM, Robert R, Liao J, Matthes E, Carlile GW, Hanrahan JW, Thomas DY. 2011. Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR. Chem Biol 18: 231-242.
61. Sloane PA, Rowe SM. 2010. Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis. Curr Opin Pulm Med 16: 591-597.
62. Snyder DS, Tradtrantip L, Yao C, Kurth MJ, Verkman AS. 2011. Potent, metabolically stable benzopyrimido-pyrrolo-oxazine-dione (BPO) CFTR inhibitors for polycystic kidney disease. J Med Chem 54: 5468-5477.
63. Solomon GM, Konstan MW, Wilschanski M, Billings J, Sermet-Gaudelus I, Accurso F, Vermeulen F, Levin E, Hathorne H, Reeves G, et al. 2010. An international randomized multicenter comparison of nasal potential difference techniques. Chest 138: 919-928.
64. Sonawane ND, Zhao D, Zegarra-Moran O, Galietta LJ, Verkman AS. 2008. Nanomolar CFTR inhibition by pore-occluding divalent polyethylene glycol-malonic acid hydrazides. Chem Biol 15: 718-728.
65. Song Y, Sonawane ND, Salinas D, Qian L, Pedemonte N, Galietta LJ, Verkman AS. 2004. Evidence against the rescue of defective DF508-CFTR cellular processing by curcumin in cell culture and mouse models. J Biol Chem 279: 40629-40633.
66. Sun X, Sui H, Fisher JT, Yan Z, Liu X, Cho HJ, Joo NS, Zhang Y, Zhou W, Yi Y, et al. 2010. Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis. J Clin Invest 120: 3149-3160.
67. Thibodeau PH, Richardson JM III, Wang W, Millen L, Watson J, Mendoza JL, Du K, Fischman S, Senderowitz H, Lukacs GL, et al. 2010. The cystic fibrosis-causing mutation DF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis. J Biol Chem 285: 35825-35835.
68. Tradtrantip L, Sonawane ND, Namkung W, Verkman AS. 2009a. Nanomolar potency pyrimido-pyrrolo-quinoxalinedione CFTR inhibitor reduces cyst size in a polycystic kidney disease model. J Med Chem 52: 6447-6455.
69. Tradtrantip L, Yangthara B, Padmawar P, Morrison C, Verkman AS. 2009b. Thiophenecarboxylate suppressor of cyclic nucleotides discovered in a small-molecule screen blocks toxin-induced intestinal fluid secretion. Mol Pharmacol 75: 134-142.
70. Van Goor F, Straley KS, Cao D, Gonzalez J, Hadida S, Hazlewood A, Joubran J, Knapp T, Makings LR, Miller M, et al. 2006. Rescue of DF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 290: L1117-L1130.
71. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, et al. 2009. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci 106: 18825-18830.
72. Van Goor F, Hadida S, Grootenhuis PD, Stack JH, Burton B, Olson E, Wine J, Frizzell RA, Ashlock M, Negulescu P. 2010. Rescue of the protein folding defect in cystic fibrosis in vitro by the investigational small molecule, VX-809. J Cyst Fibros 9: S14.
73. Wang X, Venable J, LaPointe P, Hutt DM, Koulov AV, Coppinger J, Gurkan C, KellnerW, Matteson J, Plutner H, et al. 2006. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 127: 803-815.
74. Wang W, Bernard K, Li G, Kirk KL. 2007. Curcumin opens cystic fibrosis transmembrane conductance regulator channels by a novel mechanism that requires neither ATP binding nor dimerization of the nucleotide-binding domains. J Biol Chem 282: 4533-4544.
75. Wellhauser L, Kim Chiaw P, Pasyk S, Li C, Ramjeesingh M, Bear CE. 2009. A small-molecule modulator interacts directly with DPhe508-CFTR to modify its ATPase activity and conformational stability. Mol Pharmacol 75: 1430-1438.
76. Welsh MJ, Smith AE. 1993. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73: 1251-1254.
77. Wilschanski M, Dupuis A, Ellis L, Jarvi K, Zielenski J, Tullis E, Martin S, Corey M, Tsui LC, Durie P. 2006. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Respir Crit Care Med 174: 787-794.
78. Yang H, Shelat AA, Guy RK, Gopinath VS, Ma T, Du K, Lukacs GL, Taddei A, Folli C, Pedemonte N, et al. 2003. Nanomolar affinity small molecule correctors of defective DF508-CFTR chloride channel gating. J Biol Chem 278: 35079-35085.
79. Ye L, Knapp JM, Sangwung P, Fettinger JC, Verkman AS, Kurth MJ. 2010. Pyrazolylthiazole as DF508-cystic fibrosis transmembrane conductance regulator correctors with improved hydrophilicity compared to bithiazoles. J Med Chem 53: 3772-3781.
80. Yu GJ, Yoo CL, Yang B, Lodewyk MW, Meng L, El-Idreesy TT, Fettinger JC, Tantillo DJ, Verkman AS, Kurth MJ. 2008. Potent s-cis-locked bithiazole correctors of DF508 cystic fibrosis transmembrane conductance regulator cellular processing for cystic fibrosis therapy. J Med Chem 51: 6044-6054.
81. Yu W, Kim Chiaw P, Bear CE. 2011. Probing conformational rescue induced by a chemical corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant. J Biol Chem 286: 24714-24725.
82. Zeitlin PL, Diener-West M, Rubenstein RC, Boyle MP, Lee CK, Brass-Ernst L. 2002. Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther 6: 119-126.